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ABSTRACT Matrix metalloproteinases (MMPs) are fre-
quently expressed in malignant tumor cells and are thought to
play crucial roles in tumor invasion and metastasis. Here we
report that expression of MMP9 is increased in Epstein-Barr
virus (EBV)-infected type III latency lymphoma cell lines, but
not in type I lines where latent viral gene expression is highly
restricted. Type III cell lines express abundant EBV latent
membrane protein 1 (LMP1), the principal EBV oncoprotein,
as well as the other latency proteins including the transcrip-
tional factor, EBV nuclear antigen 2, which is also required for
cell immortalization. Transfection of an LMP1 expression
plasmid in the C33A cell line increased MMP9 expression,
whereas overexpression of EBV nuclear antigen 2 did not.
Three motifs, homologous to the binding sites of NF-kB, SP-1,
and AP-1 proteins, contribute to induction of the MMP9
promoter by 12-O-tetradecanoyl-phorbol-13-acetate and tu-
mor necrosis factor a. Here we report that binding sites for
NF-kB, SP-1, and AP-1 also contribute to induction of the
MMP9 promoter by the viral protein, LMP1, mainly through
the NF-kB and, to a lesser extent, the SP-1 and AP-1 sites.
Moreover the AP-1 binding site is essential in that mutation
of it abolished reporter gene induction by LMP1. The en-
hancement of MMP9 expression was blocked by cotransfec-
tion of an IkB expression plasmid. Thus in addition to its
transforming properties, the oncoprotein LMP1 may contrib-
ute to invasiveness and metastasis of EBV-associated tumors
such as nasopharyngeal carcinoma.
Invasion into surrounding tissue is a characteristic of malig-
nant tumors such as Epstein–Barr virus (EBV)-associated
nasopharyngeal carcinoma (NPC), and both invasion and
metastasis involve sequential multistep processes. Matrix
metalloproteinases (MMPs) are a family of zinc-containing
endopeptidases that bring about the degradation of extra-
cellular matrix during physiologic tissue remodeling such as
wound healing, embryonic development, and immune cell
migration (1–3). Each MMP has a different substrate spec-
ificity; for example, interstitial collagenase (MMP1) de-
grades type I, II, and III collagens, and stromelysin 1
(MMP3) has broad substrate specificity to degrade type III
and IV collagens, proteoglycan, laminin and fibronectin
(4–7). The 72-kDa type IV collagenaseygelatinase A and the
92-kDa type IV collagenaseygelatinase B (MMP2 and
MMP9, respectively) are capable of degrading type IV and
V collagens, laminin, fibronectin, and gelatin (1, 7–9).
Several membrane-type MMPs that activate proMMP2 to
active MMP2 have also been identified (10, 11). The uncon-
trolled expression of MMPs may be relevant to the patho-
genesis of rheumatoid arthritis as well as tumor invasion and
metastasis (12, 13). MMP activity is tightly regulated, mainly
by the control of gene transcription, but also by proenzyme
activation and by the action of specific tissue inhibitors of
metalloproteinase (14, 15).
In the cascade of steps in metastasis, invasion of basement
membranes by tumor cells is thought to be critical. Two type
IV collagenases, MMP2 and MMP9, are often expressed by
malignant tumor cells, but their expression is not always
coordinated with that of MMP1 and MMP3 (16). The expres-
sion of MMP2 andyor MMP9 is thought to contribute to the
invasive character of the producer cells through ability to
degrade type IV collagen, which is a major component of
basement membrane. The release of MMP2 andyor MMP9 has
been correlated with metastasis in several systems (17–21).
However, the expression of these two collagenases is not
necessarily linked, which suggests an independent expression
pattern for both proteinases, related to differences in cellular
origin of the enzymes and transcriptional regulation (3, 12, 13,
20–23).
EBV, the causative agent of infectious mononucleosis and
oral hairy leukoplakia of the tongue, is also associated with a
variety of malignancies such as Burkitt lymphoma (BL) (24),
as well as Hodgkin’s disease (25), NPC (26), and lymphopro-
liferative disease in organ-transplant recipients and in patients
with AIDS (27). The majority of tumor cells, regardless of
type, are latently infected. Gene expression in latent infection
is restricted to six nuclear antigens [EBV nuclear antigen 1
(EBNA1), -2, -3A, -3B, -3C, and LP), three latent membrane
proteins (LMP1, -2A, and -2B), and two nonpolyadenylated
EBV-encoded RNAs (EBER1 and 2)] (28–31). Latency is
classified in three types, mainly based on the pattern of viral
protein expression. Type I cells express only EBNA1; type II
cells express EBNA1, latent membrane protein 1 (LMP1), -2A,
and -2B; and type III cells express all six nuclear antigens and
the three membrane proteins. All latently infected cells express
EBER1, and -2 (32, 33). Some of the viral latency proteins such
as LMP1 and EBNA2 are needed for transformation of cells
(34–39). There are distinctive clinical features related to type
of latency. BL, which exhibits type I latency, is characterized
by localized growth or growth in regional lymph-nodes,
whereas type III lymphomas associated with immunosuppres-
sion often disseminate to peripheral lymphoid tissue (34). In
NPC (type II latency), cervical lymph-node metastasis is the
first evidence of the malignancy in many patients (34). There-
fore, we hypothesized that viral genes expressed in type II and
type III but not in type I latency may influence the ability of
tumor to invade. In this report, we show that the expression of
MMP9, but not MMP2, is enhanced by the EBV oncoprotein,
LMP1.
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MATERIALS AND METHODS
Cell Lines. SAV I is a type I latency cell line, and SAV III
is type III; the two lines were cloned from the same parental
BL cell line (40, 41). P3HR-1 cells are derived from the Jijoye
BL cell line (42). Although both lines are type III, P3HR-1
virus is unable to induce cell immortalization due to deletion
of the genes encoding EBNA2 and EBNA-LP. BL30 and BL41
are EBV genome-negative BL cell lines. BL30-P3HR-1 and
BL41-P3HR-1 were established by single-cell cloning 2–4
weeks after infection with P3HR-1 virus. BL30-B95–8 and
BL41-B95–8 were obtained by infection with B95–8 virus (43,
44). Cells were maintained in RPMI 1640 medium supple-
mented with 10% fetal bovine serum and antibiotics. C33A
epithelial cells, derived from human papilloma virus-negative
cervical carcinoma, were obtained from the ATCC and cul-
tured at 37°C in DMEM supplemented with 10% fetal bovine
serum and antibiotics.
Plasmids. The LMP1 ORF was cut from pSV2 gptMTLM
(38) and subcloned downstream of the cytomegalovirus im-
mediate-early promoter in pcDNA3 (Invitrogen). An EBNA2
expression plasmid was constructed as described previously
(45). The cytomegalovirus immediate-early promoter-driven
IkB expression plasmid was obtained from Albert Baldwin
(46). A series of 59 f lanking sequence of MMP9 were inserted
upstream of the chloramphenicol acetyltransferase (CAT)
reporter gene as described (16).
Transient Transfection and Conditioned Media. C33A cells
were transfected with 6 mg of appropriate reporter and effector
plasmids by using Lipofectamine (GIBCOyBRL) following
the manufacturer’s protocol. Transfected cells were cultured in
DMEM with 10% fetal bovine serum overnight then in
DMEM with neither fetal bovine serum nor antibiotics for 24
hr at 37°C. Lymphoid cells were cultured in AIM-V (GIBCOy
BRL) for 48 hr to provide conditioned media for gelatin
zymography. Transfection efficiency was monitored by co-
transfection with a b-galactosidase reporter construct (67).
Gelatin Zymography. MMP2 and MMP9 were assayed by
gelatinolytic activity by means of gelatin zymography as re-
ported (47). The conditioned medium was mixed with SDS
sample buffer [50 mM TriszHCl (pH 6.8), 10% glycerol, 1%
SDS, 0.01% bromophenol blue] in the absence of reducing
agent to denature MMPs and to dissociate any complexes with
tissue inhibitors of metalloproteinases. The mixture was then
incubated at 37°C for 20 min, and SDSyPAGE containing
gelatin at a final concentration of 0.1% was performed. After
electrophoresis, the gel was rinsed in 2.5% Triton-X for 1 hr
and then incubated for 24 hr at 37°C in 50 mM TriszHCl (pH
7.6), 150 mM NaCl, 10 mM CaCl2, and 0.02% NaN3. The
MMPs were identified following staining of the gel in 0.1%
Coomassie blue R250 (Sigma) dissolved in 40% methanol,
10% acetic acid and destaining in the same solution, but
without Coomassie blue. Gelatinolytic activity was visualized
as a clear band against a dark background of stained gelatin.
This is the most sensitive method for identification of MMP2
and MMP9. MMP2 is detected by the clear band appearing at
72 kDa and MMP9 at 92 kDa (1–15, 17–19).
Western Blot Analysis. Protein extracts were obtained from
1.0 3 106 of lymphoid cells then mixed with 23 SDS sample
buffer containing reducing agent. After SDSyPAGE, the
proteins were transferred to Immobilon membranes (Milli-
pore) with the Hoefer Semi-Dry transfer apparatus. Nonspe-
cific reactivity was blocked by incubation overnight in Tris-
buffered saline solution containing 0.1% Tween 20 and 5%
nonfat dried milk. The membrane was then incubated with
primary antibody to LMP1 (Dako 1:50 dilution) and with
antiserum to EBNA2 for 2 hr (44). Secondary antibody
(1:3,000 dilution) was used to detect bound primary antibody.
Reactive protein was detected by enhanced chemilumines-
cence (Amersham). For Western blotting for MMP9 condi-
tioned medium was concentrated 20-fold by vacuum. MMP9
protein was detected with primary antiserum (Fuji Chemical,
Takaoka, Japan).
Electrophoretic Mobility Shift Assay. Nuclear extracts were
prepared from C33A cells transfected with an LMP1 expres-
sion plasmid (48). Synthetic oligonucleotides used for probes
were identical to the NFkB or AP-1 nuclear factor binding
sequences in the promoter region of MMP9 (16). The oligo-
nucleotides were labeled with [a-32P]CTP with the use of
Klenow DNA polymerase. The unlabeled oligonucleotides
were used for competition. Nuclear extracts were incubated in
12 mM Hepes buffer, 12% glycerol, 4 mM TriszHCl (pH 7.9),
1 mM EDTA, and 3 mg poly(dI-dC) with 50,000 cpm labeled
probe. The mixture was analyzed by 4.8% polyacrylamide gel
in 0.53 TBE buffer (90 mM Trisy64.6 mM boric acidy2.5 mM
EDTA, pH 8.3).
CAT Reporter Assay. CAT assays were performed with
extracts of C33A cells after transient transfection. Construc-
tion of the MMP9 promoter reporter series has been described
(16). Cells were incubated 48 hr after transfection, then
harvested; acetylated [14C] chloramphenicol was quantitated
with a PhosphorImager (Molecular Dynamics).
RESULTS
MMP9 Activity in B-Lymphoblastoid Cell Lines. Assay of
MMP gelatinolytic activity in lymphoblastoid cells growing in
culture showed that MMP9 expression correlates with EBV
infection and a form of latency EBV (type III) in which all of
the EBV proteins needed for cell transformation are ex-
pressed. Specifically both MMP9 enzymatic activity (Fig. 1
Top) and protein (Fig. 1 Middle) are expressed in SAV III,
BL30B95, BL41 B95, and Jijoye cells in which the EBV-
encoded proteins, LMP-1, EBNALP, and EBNA-2 are ex-
pressed. Because the LMP-1 promoter is activated by EBNA2
(44), we determined LMP-1 protein expression. Western blot
analysis showed that LMP-1 is expressed in these same cell
lines (Fig. 1 Bottom). Neither MMP9 nor LMP-1 is expressed
in the EBV-negative cells (BL 30, and BL 41), type I cells (SAV
1) or lines in which the EBNA2 gene is deleted and LMP-1
expression is low or not detectable (P3HR1, BL30 P3HRI, and
BL41-P3HR1). Therefore one or more of the EBV transform-
ing proteins is necessary and perhaps sufficient for induction
of MMP9 expression. In summary, expression of MMP9
FIG. 1. MMP9 and MMP2 activity in EBV-infected type I and type
III lymphoblastoid cells. SAV I is a type I BL line, and SAV III is a
sister type III line. BL30 and BL 41 are EBV-negative BL lines.
BL30-P3HR-1, BL30-B95–8, BL41-P3HR-1, and BL41-B95–8 lines
are infected with P3HR-1 virus (EBNA2 deleted) or B95–8 virus.
Jijoye is the parental BL line of P3HR-1 and has intact EBNA2 gene.
(Top) Gelatinolytic activity; (Middle) Western blot of MMP9; (Bottom)
Western blot of LMP1. Lymphoid cells (2.0 3 106) were cultured in 1
ml media for 48 hr. After centrifugation, supernatant fluid was
prepared for zymography and the pellet for Western blot analysis as
described in Materials and Methods.
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correlated with type III latency and, specifically, with expres-
sion of LMP1.
Low levels of 72-kDa MMP2 activity were also detected in
SAV III, BL30-B95–8 and BL41-B95–8 cells, but not in Jijoye.
There was not a clear or consistent difference among these cell
lines (Fig. 1). Therefore, EBV infection did not appear to
induce MMP2 activity.
MMP2 and MMP9 Activity in Cells Transfected with EBV
Latency Genes. Since some of the cell lines showing gelatino-
lytic activity have an EBNA2 gene deletion that also causes
LMP1 downregulation, the effect of LMP1 and EBNA2
expression on MMP9 production was determined by transfec-
tion of either LMP1 or EBNA2 expression plasmids into
EBV-negative C33A cells. Enhancement of 92-kDa MMP9
activity was detected in LMP1-transfected C33A cells, but not
in EBNA2-transfected C33A cells (Fig. 2a). The expression of
LMP1 and EBNA2 proteins was confirmed by Western blot
(Fig. 2b). MMP2 gelatinolytic activity was not significantly
affected by either viral protein (Fig. 2a). Thus, the enhanced
MMP9 activity detected in type III cells appears to be due to
expression of LMP1.
Inhibition of MMP9 Expression by IkB. LMP1 has been
shown to activate the NF-kB pathway (50–53). Therefore, the
inhibitory effect of IkB on LMP1-mediated MMP9 expression
was examined. Cotransfection of IkB and LMP1 expression
FIG. 2. MMP9 and MMP2 activity in EBV-negative cells trans-
fected with EBV oncoprotein LMP1 or EBNA2. (Top) Gelatinolytic
activity of C33A cells transfected with LMP1 and EBNA2. (Middle and
Bottom) Immunoblots for LMP1 and EBNA2 protein. Cells (4.0 3 105)
were placed in three sets of 60-mm culture plates 12 hr before
transfection. Samples were prepared for zymography, and LMP1 and
EBNA2 protein detection.
FIG. 3. IkB inhibits the enhancement of MMP9 expression by
LMP1. (a) Gelatin zymography. Samples of C33A cells were prepared
as described in Materials and Methods. (b) CAT assays. The effector
plasmids were cotransfected with 2670 CAT (full-length MMP9
promoter construct). The mean values and SDs represented were
obtained from three experiments.
FIG. 4. Induction of NF-kB and AP-1 DNA-binding activity in
LMP1-transfected cells. Nuclear extracts from C33A cells transfected
either with or without LMP1 expression plasmid were mixed with
either NF-kB or AP-1 32P-labeled probes. Excesses of nonlabeled
NF-kB, NF-kB mutant, AP-1 and AP-1 mutant probes (3100) were
used as competitors (NF-kB, 59-GATCGGGTTGCCCCAGTG-
GAATTCCCCAGCCTT-3; NF-kB mut, 59-GATCGGGTTGC-
CCCAGTTTAATTCCCCAGCCTT-39; AP-1, 59-GATCTTCTA-
GACCGGATGAGTCATAGCTG-39; AP-1 mut, 59-GATCTTCTA-
GACCGGATAAGGCATAGCTG). Each of the mutant competitor
oligonucleotides has two nucleotide substitutions as indicated by bold
letters in binding sequence. Underlined letters indicate binding se-
quences in the promoter of the MMP9 gene. NS, nonspecific binding.
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plasmids repressed the gelatinolytic activity of MMP9 whereas
that of MMP2 was not affected (Fig. 3a). To confirm the effect
of IkB, assays were also performed with the MMP9 promoter
CAT reporter construct. Compared with activation produced
by LMP1 alone, cotransfection of IkB repressed CAT activity
(Fig. 3b). IkB by itself produced little effect. This result
suggested that enhancement of MMP9 expression by LMP1 is,
at least in part, mediated by the NF-kB signal pathway.
Induction of NFkB and AP-1 by LMP1 Transfection. LMP1
interacts with tumor necrosis factor (TNF) receptor-associated
factors and activates several nuclear factors including NF-kB
(50, 52, 53). Three such factors, NF-kB, SP-1, and AP-1, have
been identified as transactivators of MMP9 when cells were
treated with 12-O-tetradecanoyl-phorbol-13-acetate andyor
TNFa (16). Therefore, we investigated the induction and
binding of these nuclear factors to NF-kB, SP-1, and AP-1
binding sequences in the MMP9 promoter region by cotrans-
fection with LMP1. Increases in nuclear factors binding to
NF-kB binding sequence in the MMP9 promoter were de-
tected in C33A cells transfected with LMP1 (Fig. 4). An
increase in binding of nuclear factor to AP-1 sequence was also
detected. Greater protein binding to SP-1 sequence was not
detected (data not shown). Therefore, LMP1 induces the
activation or availability of NF-kB and AP-1.
Role of Nuclear Factor Binding Elements in Promoter
Activity. MMP activity is mainly regulated by the control of
gene transcription, and also by posttranslational control (14,
15). Transcription of the MMP9 promoter is stimulated by
TNFa through binding not only to NF-kB sites but also to AP-1
and SP-1 sites (16). To test the contribution of these binding
sites, plasmids with deletions and point mutations in three sites
in the MMP9 promoter were cotransfected with the LMP1
expression vector (Fig. 5). Deletion of the NF-kB site (2599
CAT) dramatically reduced but still retained some MMP9
promoter activity. The 290 CAT construct, which only con-
tains the AP-1 binding site and TATA box, again decreased
CAT activity but still retained some promoter activity. An
additional deletion to include the AP-1 site (273 CAT)
abolished CAT activity. Mutational analysis of these binding
sites revealed that point mutation of the NF-kB binding site
(kb mut CAT) reduced CAT activity more dramatically than
the deletional construct 2599 CAT. Mutation of the SP-1 site
also decreased CAT activity, but there was still 2-fold activa-
tion (SP-1 mut CAT). Mutation of the AP-1 site completely
abolished CAT activity (AP-1 mut CAT) (Fig. 5). Therefore,
the AP-1 binding site is essential for activation of the MMP9
promoter by LMP1, and the NF-kB site as well as the SP-1 site
contribute to activation.
DISCUSSION
LMP1 is necessary for transformation of B lymphocytes and is
the only EBV latency gene capable of transforming rodent
fibroblasts (37, 38). Thus, LMP1 is thought to have a significant
role in initiating EBV-associated lymphoproliferative disease
and EBV-related malignancies (34–36, 40). Although LMP1
has until now been characterized mainly with respect of its
primary oncogenic capacity, here we show that LMP1 may
have an additional level of function, namely, the ability to
induce cellular genes, specifically MMP9, that promote inva-
sion and metastasis. LMP1 is expressed in at least 70% of NPC
and all EBV-infected preinvasive lesions (54, 55). NPC, which
exhibits type II latency, frequently disseminates clinically into
regional lymph-nodes before forming a mass in the primary
site, whereas BL (type I) is prone to form a localized mass
before it disseminates (34). Moreover, LMP1 reduces expres-
sion of E-cadherin, another cell invasive factor, in a human
keratinocyte cell line (56). Our results indicate therefore that
LMP1 has a dual function, contributing not only to cell
transformation but also invasiveness of EBV-associated tu-
mors categorized as type II and III by enhancing MMP9
activity. Interestingly, the v-src oncogene not only promotes
cellular transformation, but also transactivates expression of
MMP9 (57). Finally, in head-and-neck squamous cell carcino-
mas originating in the oropharynx, which have not been
associated with EBV infection, MMP1, -2, -7, -9, -11, and
MT1-MMP are overexpressed (47, 58–61). Levels of these
enzymes in NPC have not yet been reported.
Aggregation of LMP1 in the plasma membrane evokes
activation of the TNF receptor downstream signaling pathway
(50). LMP1 is comprised of 386 amino acids, of which the
carboxy-terminal 200 amino acids are in the cytoplasmic
domain of the protein. This portion of the protein contains two
functional domains. One, the proximal domain (amino acids
187–231), interacts with TNF receptor-associated factors and
mediates NF-kB activation (53). The other, the distal domain
(amino acids 352–386) whose interaction partner has not been
identified, mediates higher level NF-kB activation than the
proximal domain (62, 63). Although the activation of the
NF-kB signal pathway by LMP1 has been emphasized, the
entire pathway has not been delineated. Induction of epider-
mal growth factor receptor is activated by LMP1 through a
signal pathway distinct from the NF-kB pathway (52). There-
FIG. 5. Deletional and mutational analysis of the cis-elements required for LMP1-induced MMP9 promoter activity. Arrow indicates
transcription start site and ‘‘X’’ the sites of mutation in the MMP9 59 f lanking sequence inserted upstream of the CAT gene. Open and solid bars
represent CAT activity of pcDNA3 and cytomegalovirus-LMP1-transfected C33A cells, respectively. The mean values and error bars represent the
results of two sets of three experiments.
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fore, the elements responsible for the activation of MMP9 may
differ from those that promote transformation and are being
investigated.
Correlation between the production of type IV collagenases
(MMP2 and MMP9) and spontaneous metastasis in a rat
model (20, 21) has been reported. MMP9 is secreted by normal
alveolar macrophages, granulocytes, osteoclasts, invading tro-
phoblasts, and transformed cell lines, but not by fibroblasts.
MMP2 is constitutively expressed in most fibroblast and some
transformed cell lines (3, 12, 22). The promoter of the MMP9
gene contains NF-kB, SP-1, AP-1 binding sites, and a TATA box,
whereas the MMP2 promoter contains AP-2 and SP-1 binding
sites, but no TATA box (16, 22). The transcriptional factor Ets
may also be involved in the transactivation of MMP9 in H-ras and
c-myc-transformed rat cell lines (64). Finally, the fact that LMP1
did not induce MMP2 expression may be related in part to the
lack of an NF-kB site in the MMP2 promoter (22).
EBNA2, which also activates NF-kB, did not significantly
increase MMP9 expression. Chen et al. reported that the
induction of NF-kB by EBNA2 was weaker than by LMP1 in
EBV-negative cells (65). Our results indicate that the induction
of NF-kB by EBNA2 alone is not sufficient to transactivate the
MMP9 promoter to induce MMP9 enzyme activity.
Finally we show that the enhancement of expression of MMP9
by LMP1 is partially blocked by IkB. These results suggest that
type II and type III malignancies such as NPC, Hodgkin disease
(type II), and AIDS-related lymphoma (type III) may use MMP9
for metastasis. Therefore an agent that mimics IkB may be
effective in preventing metastasis of these tumors (66).
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